Abstract
Proton pump inhibitors are the most effective therapy for all the acid-dependent diseases. Pantoprazole has been used since 1997 and it has a precise and predictable profile of activity. Pantoprazole maintains its stability in higher gastric pH with concomittant antiacids. Its constant bioavaibility and maximal blood levels are achieved after the first dose. Pantoprazole is approved for a variety of gastric acid-related diseases: gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, functional dyspepsia, NSAID-induced gastropathy treatment and prevention, and Zollinger-Ellison syndrome. Pantoprazole has been shown to have no significant interactions with other medications: especially important with antiplatelet drugs (clopidogrel), but also antipyrine, carbamazepine, ciclosporin, clarithromycin, diclofenac, naproxen, nifedipine, oral contraceptives, tacrolimus, theophylline, warfarin, and also ethanol. Pantoprazole is the very good choice particularly in patients taking multiple concomitant medications – such as the elderly or those receiving drugs with a narrow therapeutic window. Even in the long-term therapy, pantoprazole seems to be well tolerated with no identified safety concerns.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
